ipharmacenter Consulting services

Switzerland’s new understanding with the US goes beyond a minor tariff tweak and directly touches the country’s role as a pharma and med‑tech hub. Under a November memorandum of understanding, Washington will cap the country‑specific additional tariff on Swiss goods at 15%, bringing Switzerland into line with the EU and EFTA - while key pharmaceutical products remain largely exempt from the surcharge but under continued scrutiny.​   What the Switzerland–United States deal doe

NICE’s decision to accept higher cost‑per‑QALY ratios is more than a technical parameter change; it reflects a domestic adjustment to a broader bargain the UK has struck with the United States to pay more for branded medicines in return for zero tariffs on British pharmaceutical exports. That combination of trade and health‑policy concessions is likely to shape how other tax‑funded health systems define value, manage finite drug budgets and approach negotiations with global m